Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,253.61
+0.6%
+44.60
Arrow-Thin-Down
DJI
49,768.93
+0.2%
+116.79
Arrow-Thin-Down
NASDAQ
25,147.09
+1.0%
+254.77
Arrow-Thin-Down
Bitcoin
$78,237.00
+2.7%
+$2,024.91
Arrow-Thin-Down
AAPL
$283.56
+4.5%
+$12.21
Arrow-Thin-Down
AMZN
$268.64
+1.4%
+$3.58
Arrow-Thin-Down
GOOG
$380.70
-0.3%
-$1.24
Arrow-Thin-Down
META
$614.72
+0.5%
+$2.81
Arrow-Thin-Down
MSFT
$414.28
+1.6%
+$6.50
Arrow-Thin-Down
NVDA
$199.51
-0.0%
-$0.06
Arrow-Thin-Down
TSLA
$390.97
+2.4%
+$9.34
Most Active StocksDaily Stock GainersDaily Stock Losers
Ptc Therapeutics logo

Ptc Therapeutics

(NASDAQ) PTCT

Current Price$64.52
Market Cap$5.39B
Since IPO (2013)+295%
5 Year+58%
1 Year+31%
1 Month-5%

Ptc Therapeutics Financials at a Glance

Market Cap

$5.39B

Revenue (TTM)

$1.73B

Net Income (TTM)

$682.64M

EPS (TTM)

$7.74

P/E Ratio

8.41

Dividend

$0.00

Beta (Volatility)

0.99 (Low)

Price

$64.52

Volume

76,111.837

Open

$65.08

Previous Close

$65.06

Daily Range

$63.18 - $67.34

52-Week Range

$35.95 - $87.50

PTCT News

BuyAlert-Blue.png

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing

Jake LerchMar 3, 2026
BuyAlert-Green.png

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?

Jonathan PoncianoDec 3, 2025
BuyAlert-Red.png

Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You?

Jonathan PoncianoDec 2, 2025
SellAlert-Purple.png

A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000

Cory RenauerNov 29, 2025
SellAlert-Blue.png

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why

Jonathan PoncianoNov 18, 2025
GettyImages-1369508549-1200x800-5b2df79

Here's Why Shares in PTC Therapeutics Soared This Week

Lee SamahaSep 5, 2025
Foolcom-Featured.png

PTCT Earnings Beat but Sales Drop 4%

Motley Fool Markets TeamAug 7, 2025
Two people seated at a lab desk featuring a PC screen and microscope

Why PTC Therapeutics Soared 15% Higher Today

Eric VolkmanOct 19, 2023
Page 1

PTCT: Motley Fool Moneyball Superscore

73

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ptc Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

991

CEO

Matthew B. Klein, MD

Website

www.ptcbio.com

Headquarters

Warren, NJ 07080, US

PTCT Financials

Key Financial Metrics (TTM)

Gross Margin

91%

Operating Margin

49%

Net Income Margin

39%

Return on Equity

0%

Return on Capital

44%

Return on Assets

23%

Earnings Yield

11.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.39B

Shares Outstanding

82.77M

Volume

76.11K

Avg. Volume

1.15M

Financials (TTM)

Gross Profit

$1.66B

Operating Income

$856.51M

EBITDA

$887.66M

Operating Cash Flow

$711.20M

Capital Expenditure

$8.86M

Free Cash Flow

$702.34M

Cash & ST Invst.

$1.95B

Total Debt

$492.28M

Ptc Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$164.68M

-22.7%

Gross Profit

$148.38M

-24.6%

Gross Margin

90.10%

N/A

Market Cap

$5.39B

N/A

Market Cap/Employee

$5.74M

N/A

Employees

939

N/A

Net Income

$134.97M

-104.8%

EBITDA

$70.99M

-51.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$1.45B

+209.1%

Accounts Receivable

$181.62M

+14.5%

Inventory

$79.65M

+243.4%

Long Term Debt

$190.17M

-91.4%

Short Term Debt

$302.12M

+11.4%

Return on Assets

23.45%

N/A

Return on Invested Capital

44.09%

N/A

Free Cash Flow

$36.65M

-0.4%

Operating Cash Flow

$34.27M

-14.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TGTXTG Therapeutics, Inc.
$33.89+0.32%
ALKSAlkermes plc
$33.75+0.12%
PTGXProtagonist Therapeutics, Inc.
$98.34-0.64%
CRNXCrinetics Pharmaceuticals, Inc.
$39.55+1.99%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.11+0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.63+0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.99+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$50.48-0.02%

Questions About PTCT

What is the current price of Ptc Therapeutics?

Ptc Therapeutics is trading at $64.31 per share.

What is the 52-week range for Ptc Therapeutics?

Over the past 52 weeks, Ptc Therapeutics has traded between $35.95 and $87.50.

How much debt does Ptc Therapeutics have?

As of the most recent reporting period, Ptc Therapeutics reported total debt of $398.70M.

How much cash does Ptc Therapeutics have on hand?

Ptc Therapeutics reported $984.65M in cash and cash equivalents in its most recent financial results.

What is Ptc Therapeutics’s dividend yield?

Ptc Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services